Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Cevostamab |
| Trade Name | |
| Synonyms | RO7187797|BFCR4350A |
| Drug Descriptions |
Cevostamab (BFCR4350A) is a bispecific antibody that targets both FCRH5 and CD3, potentially resulting in increased anti-tumor immune response and tumor cell killing (Blood (2020) 136 (Supplement 1): 42-43). |
| DrugClasses | CD3 Antibody 119 |
| CAS Registry Number | NA |
| NCIT ID | C139549 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Cevostamab | Cevostamab | 0 | 2 |
| Cevostamab + Dexamethasone + Iberdomide + Tocilizumab | Cevostamab Dexamethasone Iberdomide Tocilizumab | 0 | 1 |
| Cevostamab + Elranatamab-bcmm | Cevostamab Elranatamab-bcmm | 0 | 1 |
| Cevostamab + Lenalidomide + Tocilizumab | Cevostamab Lenalidomide Tocilizumab | 0 | 0 |
| Cevostamab + Linvoseltamab | Cevostamab Linvoseltamab | 0 | 1 |
| Cevostamab + RO7310729 + Tocilizumab | Cevostamab RO7310729 Tocilizumab | 0 | 1 |
| Cevostamab + Tocilizumab | Cevostamab Tocilizumab | 0 | 3 |